

---

# Index

## A

Adiponectin, 27  
Adrenomedullin, 18  
AHA Guidelines, 173  
Aldactone, 121  
Aldosterone, 11–17  
Aldosteronism, 15  
ALLHAT, 5  
Alpha-methyldopa, 32  
Ambulatory arterial stiffness index, 97  
Ambulatory blood pressure  
  monitoring, 4, 96, 97, 100–102  
Angiotensin 1–7, 27  
Angiotensin II, 27  
Angiotensin receptor blockers, 31  
Angiotensin-converting enzyme  
  inhibitors, 31  
Anglo-Scandinavian Cardiac Outcomes  
  Trial (ASCOT), 28  
Antagonism, 109  
Antihypertensive drugs, 108, 110, 111, 172  
Antihypertensive medications, 95  
Antihypertensive treatment, 60–63, 65, 66, 70  
Arterial baroreflex, 140, 141  
Arterial stiffness, 100  
Assessment of BP control, 68  
Associated cardiovascular risk factors, 6

## B

Bariatric surgery, 26  
Baroreflex activation, 175  
Beta blockers, 31  
Blocking the renin-angiotensin system, 174  
Blood pressure, 138–142, 156, 161, 163  
Blood pressure control, 60–62, 64, 66, 68, 71  
Blood pressure regulation, 51  
Blood volume, 51  
BP control, 2, 66  
BP is  $\geq 140/90$  mmHg, 95  
BP-lowering treatment, 61

## C

Calcium channel blockers, 31  
Cardiovascular damage, 40  
Cardiovascular risk, 61, 71  
Carotid baroreceptor stimulation, 137–142  
Chromogranin, 18  
Chronic kidney disease, 97  
Circadian variability, 97  
Concomitant diseases, 110  
Cost-benefit, 171  
Cost-benefit analysis, 175  
Cost-effectiveness, 171–175  
Cost-effectiveness of non-pharmacological  
  treatment, 173  
Cost-effectiveness of pharmacological  
  treatment, 174  
Cost-effectiveness of the new interventional  
  strategies, 174  
Cost of drug treatment, 172  
Cost-utility, 171

## D

Day-by-day BP variability, 67  
Definition of resistant hypertension, 2–4  
Diabetes, 146–149, 151  
Diagnosis, management, and assessment  
  of BP control, 64  
Diuretics, 116, 118–120, 174  
Doxazosin, 32  
Drug-resistant hypertension, 11  
Drug therapy, 122, 123

## E

Effects of drugs and conditions  
  on the RAAS, 14  
Endothelin-1, 27  
Endothelin antagonists, 122  
End-stage kidney disease, 12  
Enzymes, 107, 108

**E (cont.)**

Epidemiological studies, 1  
Eplerenone, 32

**F**

False BP control, 60, 61, 64, 66,  
69, 71  
False resistant hypertension, 60–64,  
66, 68–71  
Fibrinoid necrosis, 54  
Focal-segmental  
glomerulosclerosis, 54  
Follow Up, 101, 156, 163, 164  
FORICA, 19  
FTO, 26

**G**

Genetic factors, 26  
Genomewide association studies, 26  
Germline mutation, 19  
Glomerulosclerosis, 54  
Glucose tolerance, 25  
Guidelines, 13

**H**

24-h ambulatory BP levels, 65  
24 h ambulatory BP monitoring, 62, 96  
Health care resources, 172  
Home BP monitoring, 67  
Hyperfiltration, 13, 186  
Hyperinsulinemia, 25  
Hypertension, 23–27, 29–33, 51–55, 110  
Hypertension center, 188  
Hypertension specialist, 183, 185, 186,  
188, 189

**I**

Incremental cost-effectiveness ratio (ICER),  
175, 176  
Inflammation, 24, 27  
In-office and out-of-office bp measurement  
techniques, 56  
Insulin resistance, 147, 148, 151  
Interleukin-6, 27  
Interstitial, 54  
Interventional therapies, 63  
Ion channels, 107, 108

**K**

Kidney, 51–53, 55

**L**

Laparoscopic adrenalectomy, 16  
Left ventricular hypertrophy, 41  
Leptin, 27  
Licorice, 17  
Lifestyle, 110, 148, 151  
Long-term follow-up, 67  
Low renin, 16

**M**

Masked hypertension, 56, 97  
Masked resistant/uncontrolled hypertension  
(MRH), 64  
Medical intolerance, 4  
Metabolic syndrome, 23–25, 27, 28,  
31–33  
Metabolism, 148, 151  
Microalbuminuria, 97  
Microvascular damage, 52  
Moxonidine, 32  
Multidisciplinary approach, 183  
Multidrug therapy, 63  
Mutations, 17

**N**

Nephron loss, 52  
Nephrosclerosis, 54  
Neurohumoral, 19  
Neuronal output, 52, 54  
New Interventional treatment, 174  
Nighttime BP, 96, 102  
Nocturnal hypertension, 66  
Non-dippers, 66  
Non-dipping pattern, 98  
Non-esterified fatty acids, 27  
Non-Pharmacological treatment, 173

**O**

Obesity, 23, 146–148, 173  
Obstructive sleep apnea, 173  
Office blood pressure, 59, 67, 70  
Out-of-office BP levels, 66  
Out-of-office BP measurement  
techniques, 60, 65

**P**

Parenchymal, 52  
Perivascular adipose tissue, 27  
Pharmacodynamics, 107, 111  
Pharmacogenomics, 111  
Pharmacokinetics, 107  
Pharmacological treatment, 174, 176  
Pharmacology, 108  
Pheochromocytoma, 17  
Polycystic ovary syndrome, 29  
Polymorphisms, 111  
Potentiation, 109  
Predicting factors, 110, 111  
Prevalence, 15  
Prevalence of resistant hypertension, 4–6  
Primary aldosteronism, 15, 100  
Professional figures, 182, 183, 186, 188, 189  
Professional skill, 183  
Prognosis of resistant hypertension, 6  
Pseudoresistant hypertension, 3, 4  
Psychosocial factors, 109

**Q**

Quality adjusted life years (QALYs), 175, 177

**R**

Receptor, 17, 107  
Refractory hypertension, 102  
Remodeling, 44  
Renal angiography, 13  
Renal artery stenosis, 54, 55  
Renal denervation, 102, 175  
Renal microcirculation, 53  
Renal sympathetic nerve ablation, 28  
Renovascular, 54  
Renin, 27  
Renin assay, 185  
Renin-angiotensin-aldosterone system (RAAS), 13, 15, 19, 24, 29, 157, 162  
Renovascular hypertension (RVH), 11  
Resistance, 116, 117, 121  
Resistant hypertension, 39, 45, 46, 48, 51, 56, 59–64, 66, 68–71, 95–97, 100–102, 141, 142, 145–148, 151, 155, 156, 163, 164, 181–183, 185–187, 189  
Resistant hypertension treatment, 173–175, 177  
Response to Antihypertensive Treatment, 65  
Retention of salt, 52

Revascularization, 13  
Rheos implantable device, 175  
Rilmenidine, 32  
Risers, 66

**S**

Salt, 118, 119  
Secondary causes of hypertension, 3  
Secondary hypertension, 40, 44, 54, 78, 79, 87, 100, 160  
Self-BP measurement, 96, 102  
SLC39A8, 27  
Sleep apnea syndrome, 17, 100  
Spanish Ambulatory Blood Pressure Monitoring (ABPM) Registry, 4  
Spironolactone, 32, 174  
Statins, 28, 33  
Suboptimal medical regimen, 4  
Surveillance, 156  
Sympathetic activity, 138, 140  
Sympathetic nervous system, 24, 28  
Simplicity HTN-2 trial, 176  
Synergism, 109

**T**

Target organ damage, 62, 95  
Thiazide diuretics, 31  
TNF-alpha, 27  
Treated hypertensive patients, 61  
Treatment adherence, 61, 63, 71  
Triple drug regimen, 174  
True and false resistant hypertension, 63, 64  
True BP control, 61, 64, 69  
True resistant hypertension, 61, 62, 64, 69  
Tubular sodium reabsorption, 53  
Tubulointerstitial, 54  
Tumors secreting renin, 15

**V**

Vascular, 52  
Vascular tone, 51  
Vasoactive hormones, 51, 52

**W**

White-coat effect, 59, 61–63, 66, 67, 96  
White-coat hypertension, 56  
White-coat resistant hypertension, 101